UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported):
March 23, 2005

 

PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware

 

000-19756

 

94-3023969

(State or other jurisdiction
of incorporation)

 

(Commission File No.)

 

(I.R.S. Employer Identification No.)

 

34801 Campus Drive

Fremont, California 94555
(Address of principal executive offices)

 

Registrant’s telephone number, including area code:
(510) 574-1400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


Item 8.01 Other Events.

On March 23, 2005, Protein Design Labs, Inc., a Delaware corporation (“PDL”) announced that it has discussed with the U.S. Food and Drug Administration (“FDA”) the future development pathway for PDL’s Nuvion® (visilizumab) humanized anti-CD3 antibody being developed for the treatment of intravenous steroid-refractory ulcerative colitis.  A copy of the press release announcing PDL’s discussion with the FDA about Nuvion is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

 

Item 9.01 Financial Statements and Exhibits.

(c)           Exhibits.

Exhibit No.

 

Description

 

99.1

 

Press Release issued by Protein Design Labs, Inc. on March 23, 2005.

 

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:    March 25, 2005

 

 

PROTEIN DESIGN LABS, INC.

 

 

 

 

By:

/s/ Sergio Garcia-Rodriguez

 

 

 

Sergio Garcia-Rodriguez

 

 

Vice President, Legal, General Counsel
and Assistant Secretary

 

 

 

 

 

 

3